Eli Lilly CEO: 700K Seniors on GLP-1s Since Medicare Coverage Began

Eli Lilly's chief executive revealed Tuesday that 700,000 new senior patients have begun taking GLP-1 medications since Medicare coverage for the drugs launched in July, marking a significant expansion of access to one of the most sought-after drug classes in modern medicine. Of those newly covered patients, 70% opted for a Lilly product, underscoring the company's dominant market position in the GLP-1 space.

The figures represent the clearest picture yet of how federal insurance coverage is reshaping who can afford and access GLP-1 therapies, which have been widely praised for their effectiveness in treating obesity and type 2 diabetes but have long carried price tags that put them out of reach for many Americans on fixed incomes.

Read more Trump's Press Pool Ban Limits Public View of White House →

The CEO's disclosure comes as policymakers and health economists continue to debate the long-term fiscal implications of broad Medicare coverage for GLP-1s. With hundreds of thousands of seniors now initiating treatment in just a matter of months, analysts are watching closely to determine whether the downstream health benefits — including potential reductions in cardiovascular events and hospitalizations — can offset the program's near-term drug costs.

Lilly's commanding 70% share of newly covered Medicare patients signals that the company's commercial infrastructure and physician relationships give it a critical edge over rivals at the precise moment when the government is opening the market to millions of older Americans who were previously priced out. The trend is likely to intensify scrutiny over drug pricing negotiations and rebate structures as enrollment grows.

Continue reading at US Top News and Analysis.